{"url_path":"/sec/plx/10-k/2026/item-15","section_key":"item-15","section_title":"Item 15 Exhibits and Financial Statement Schedules","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-03-18","source_url":"https://www.sec.gov/Archives/edgar/data/1006281/0001104659-26-029858-index.html","accession_number":"0001104659-26-029858","cik":"0001006281","ticker":"PLX","issuer_name":"Protalix BioTherapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1006281/0001104659-26-029858-index.html","primary_entity_key":"0001006281","primary_entity_name":"Protalix BioTherapeutics, Inc."},"word_count":1662,"has_tables":true,"body_markdown":"Item 15.       Exhibits and Financial Statement Schedules\n\nThe following documents are filed as part of this Annual Report on Form 10-K:\n\n1.*Financial Statements.* The following Consolidated Financial Statements of Protalix BioTherapeutics, Inc. are included in Item 8 of this Annual Report on Form 10-K:\n\n​\n\n​\n\n**  ​ ​ ​**\n\n**Page**\n\n** **\n\n[Report of Independent Registered Public Accounting Firm](#ReportofIndependentRegisteredPublicAccou) (PCAOB name: Kesselman & Kesselman C.P.A.s and PCAOB ID: 1309)\n\n​\n\nF-2\n\n[Consolidated Balance Sheets as of December 31, 2024, and 2025](#CONSOLIDATEDBALANCESHEETS_216383)\n\n​\n\nF-4\n\n[Consolidated Statements of Operations for the years ended December 31, 2023, 2024, and 2025](#CONSOLIDATEDSTATEMENTSOFOPERATIONS_58886)\n\n​\n\nF-5\n\n[Consolidated Statements of Changes in Stockholders’ Equity (Capital Deficiency) for the years ended December 31, 2023, 2024, and 2025](#CONSOLIDATEDSTATEMENTSOFCHANGESINCAPITAL)\n\n​\n\nF-6\n\n[Consolidated Statements of Cash Flows for the years ended December 31, 2023, 2024, and 2025](#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_110294)\n\n​\n\nF-7\n\n[Notes to Consolidated Financial Statements](#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_5)\n\n​\n\nF-9\n\n​\n\n2. *Financial Statement Schedule.* Financial statement schedules have been omitted since they are either not required, are not applicable or the required information is shown in the consolidated financial statements or related notes.\n\n3. *Exhibits.*\n\n​\n\n \n\n \n\n \n\n \n\n**Incorporated by Reference**\n\n \n\n \n\n**Exhibit********Number**\n\n  ​ ​ ​\n\n**Exhibit Description**\n\n  ​ ​ ​\n\n**Form**\n\n  ​ ​ ​\n\n**File********Number**\n\n  ​ ​ ​\n\n**Exhibit**\n\n  ​ ​ ​\n\n**Date**\n\n  ​ ​ ​\n\n**Filed********Herewith**\n\n1.1\n\n​\n\n[At the Market Offering Agreement, dated February 27, 2023, between the Company and H.C. Wainwright & Co., LLC](https://www.sec.gov/Archives/edgar/data/1006281/000155837023002104/plx-20230227xex1d1.htm)\n\n​\n\n8-K\n\n \n\n001-33357\n\n \n\n1.1\n\n​\n\nFebruary 27, 2023\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n1.2\n\n​\n\n[Letter Agreement dated March 17, 2025 to the At the Market Offering Agreement, dated February 27, 2023, between the Company and H.C. Wainwright & Co., LLC](https://www.sec.gov/Archives/edgar/data/1006281/000155837025003143/plx-20250317xex1d1.htm)\n\n​\n\n8-K\n\n \n\n001-33357\n\n \n\n1.1\n\n​\n\nMarch 17, 2025\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n1.3\n\n​\n\n[Letter Agreement dated August 22, 2025 to the At the Market Offering Agreement, dated February 27, 2023, between the Company and H.C. Wainwright & Co., LLC](https://www.sec.gov/Archives/edgar/data/1006281/000110465925081924/tm2524070d1_ex1-1.htm)\n\n​\n\n8-K\n\n \n\n001-33357\n\n \n\n3.1\n\n \n\nAugust 22, 2025\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n3.1\n\n \n\n[Certificate of Incorporation of the Company](https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm)\n\n \n\n8-K\n\n \n\n001-33357\n\n \n\n10.1\n\n \n\nApril 1, 2016\n\n​\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.2\n\n \n\n[Amendment to Certificate of Incorporation of the Company](https://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm)\n\n \n\nDef 14A\n\n \n\n001-33357\n\n \n\nAppen. A\n\n \n\nJuly 1, 2016\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.3\n\n \n\n[Second Amendment to Certificate of Incorporation of the Company](https://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm)\n\n \n\nDef 14A\n\n \n\n001-33357\n\n \n\nAppen. A\n\n \n\nOctober 17, 2018\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.4\n\n \n\n[Third Amendment to Certificate of Incorporation of the Company](https://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm)\n\n \n\n8-K\n\n \n\n001-33357\n\n \n\n3.1\n\n \n\nDecember 20, 2019\n\n \n\n74\n\n[Table of Contents](#TOC)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.5\n\n \n\n[Fourth Amendment to Certificate of Incorporation of the Company](https://www.sec.gov/Archives/edgar/data/1006281/000155837022013560/plx-20220630xex3d5.htm)\n\n \n\n10-Q\n\n \n\n001-33357\n\n \n\n3.5\n\n \n\nAugust 15, 2022\n\n \n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n3.6\n\n \n\n[Fifth Amendment to Certificate of Incorporation of the Company](https://www.sec.gov/Archives/edgar/data/1006281/000155837023013483/plx-20230630xex3d6.htm)\n\n \n\n10-Q\n\n \n\n001-33357\n\n \n\n3.6\n\n \n\nAugust 7, 2023\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n3.7\n\n \n\n[Second Amended and Restated Bylaws of the Company](https://www.sec.gov/Archives/edgar/data/1006281/000155837025007063/plx-20250331xex3d7.htm)\n\n \n\n10-Q\n\n \n\n001-33357\n\n \n\n3.7\n\n \n\nMay 9, 2025\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4.1†\n\n \n\n[Form of Restricted Stock Agreement/Notice](https://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm)\n\n \n\n8-K\n\n \n\n001-33357\n\n \n\n4.1\n\n \n\nJuly 18, 2012\n\n \n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n4.2†\n\n​\n\n[Form of Stock Option Agreement (Executives)](https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d8.htm)\n\n​\n\n10-Q\n\n​\n\n001-33357\n\n \n\n4.8\n\n​\n\nAugust 10, 2020\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n4.3\n\n​\n\n[Form of Stock Option Agreement (Standard)](https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d9.htm)\n\n​\n\n10-Q\n\n​\n\n001-33357\n\n \n\n4.9\n\n​\n\nAugust 10, 2020\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n4.4\n\n​\n\n[Description of Capital Stock](plx-20251231xex4d4.htm)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nX\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n10.1\n\n \n\n[Lease Agreement between Protalix Ltd. and Angel Science Park (99) Ltd., dated as of October 28, 2003 as amended on April 18, 2005](https://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w9.htm)\n\n \n\n8-K\n\n \n\n001-33357\n\n \n\n10.9\n\n \n\nJanuary 8, 2007\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n10.2\n\n \n\n[Unprotected Lease Agreement](https://www.sec.gov/Archives/edgar/data/1006281/000095013608001374/file2.htm)\n\n \n\n10-K\n\n \n\n001-33357\n\n \n\n10.21\n\n \n\nMarch 17, 2008\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n10.3††\n\n \n\n[Amended and Restated Agreement between Protalix Ltd. and Comercio e Serviços Ltda. dated June 17, 2013](https://www.sec.gov/Archives/edgar/data/1006281/000155837021007157/plx-20210331xex10d1.htm)\n\n \n\n10-Q\n\n \n\n001-33357\n\n \n\n10.1\n\n \n\nMay 14, 2021\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n10.4††\n\n \n\n[Technology Transfer and Supply Agreement made as of June 18, 2013 by and between Protalix Ltd. and Fundação Oswaldo Cruz](https://www.sec.gov/Archives/edgar/data/1006281/000155837021007157/plx-20210331xex10d2.htm)\n\n \n\n10-Q\n\n \n\n001-33357\n\n \n\n10.2\n\n \n\nMay 14, 2021\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n10.5††\n\n​\n\n[Binding Term Sheet between Protalix Ltd. and Chiesi Farmaceutici S.p.A.](https://www.sec.gov/Archives/edgar/data/1006281/000155837021007157/plx-20210331xex10d3.htm)\n\n​\n\n10-Q\n\n \n\n001-33357\n\n​\n\n10.3\n\n \n\nMay 14, 2021\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n10.6††\n\n \n\n[Amended and Restated Exclusive License and Supply Agreement by and between Pfizer Inc. and Protalix Ltd., dated October 12, 2015](https://www.sec.gov/Archives/edgar/data/1006281/000110465925110824/plx-20250930xex10d1.htm)\n\n \n\n10-Q\n\n \n\n001-33357\n\n \n\n10.1\n\n \n\nNovember 13, 2025\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n10.7††\n\n \n\n[Exclusive License and Supply Agreement dated as of October 17, 2017, made by and between Protalix Ltd. and Chiesi Farmaceutici S.p.A.](https://www.sec.gov/Archives/edgar/data/1006281/000114420418013053/tv486893_ex10-16.htm)\n\n \n\n10-K\n\n \n\n001-33357\n\n \n\n10.16\n\n \n\nMarch 6, 2018\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n10.8††\n\n \n\n[Exclusive U.S. License and Supply Agreement dated as of July 23, 2018,](https://www.sec.gov/Archives/edgar/data/1006281/000114420418057990/tv505296_ex10-1.htm)\n\n \n\n10-Q\n\n \n\n001-33357\n\n \n\n10.1\n\n \n\nNovember 7, 2018\n\n​\n\n​\n\n75\n\n[Table of Contents](#TOC)\n\n[made by and between Protalix Ltd. and Chiesi Farmaceutici S.p.A.](https://www.sec.gov/Archives/edgar/data/1006281/000114420418057990/tv505296_ex10-1.htm)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n10.9†\n\n \n\n[Employment Agreement made effective as of May 20, 2019, by and between Protalix Ltd. and Mr. Dror Bashan](https://www.sec.gov/Archives/edgar/data/1006281/000114420419027423/tv522023_ex10-1.htm)\n\n \n\n8-K\n\n \n\n001-33357\n\n \n\n10.1\n\n \n\nMay 21, 2019\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n10.10†\n\n​\n\n[Amended and Restated Pro BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended](https://www.sec.gov/Archives/edgar/data/1006281/000155837024009567/plx-20240627xex10d1.htm)\n\n​\n\n8-K\n\n​\n\n001-33357\n\n \n\n10.1\n\n​\n\nJune 28, 2024\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n10.11††\n\n​\n\n[Fill/Finish Agreement effective on August 29, 2022 made by and between Chiesi Farmaceutici S.p.A and Protalix Ltd.](https://www.sec.gov/Archives/edgar/data/1006281/000155837022017554/plx-20220930xex10d1.htm)\n\n​\n\n10-Q\n\n \n\n001-33357\n\n \n\n10.1\n\n​\n\nNovember 14, 2022\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n10.12††\n\n​\n\n[Letter Agreement dated August 29, 2022 from Chiesi Farmaceutici S.p.A to Protalix Ltd.](https://www.sec.gov/Archives/edgar/data/1006281/000155837022017554/plx-20220930xex10d2.htm)\n\n​\n\n10-Q\n\n \n\n001-33357\n\n​\n\n10.2\n\n​\n\nNovember 14, 2022\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n10.13†\n\n​\n\n[Employment Agreement made effective as of June 13, 2025, by and between Protalix Ltd. and Mr. Gilad Mamlok](https://www.sec.gov/Archives/edgar/data/1006281/000155837025009308/plx-20250613xex10d1.htm)\n\n​\n\n8-K\n\n \n\n001-33357\n\n \n\n10.1\n\n \n\nJuly 21, 2025\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n19\n\n​\n\n[Insider Trading and Blackout Policy](https://www.sec.gov/Archives/edgar/data/1006281/000155837025003039/plx-20241231xex19.htm)\n\n​\n\n10-K\n\n​\n\n001-33357\n\n \n\n19\n\n \n\nMarch 17, 2025\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n21.1\n\n \n\n[Subsidiaries](https://www.sec.gov/Archives/edgar/data/1006281/000155837025003039/plx-20241231xex21d1.htm)\n\n \n\n10-K\n\n​\n\n001-33357\n\n \n\n19\n\n \n\nMarch 17, 2025\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n23.1\n\n \n\n[Consent of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member of PricewaterhouseCoopers International Limited, independent registered public accounting firm for the Registrant](plx-20251231xex23d1.htm)\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\nX\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n24.1\n\n​\n\n[Power of Attorney (included on the signature page to this Annual Report on Form 10-K)](#POWER_OF_ATTORNEY)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nX\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n31.1\n\n \n\n[Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](plx-20251231xex31d1.htm)\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\nX\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n31.2\n\n \n\n[Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](plx-20251231xex31d2.htm)\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\nX\n\n​\n\n76\n\n[Table of Contents](#TOC)\n\n \n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n32.1\n\n \n\n[18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer](plx-20251231xex32d1.htm)\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\nX\n\n \n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n32.2\n\n \n\n[18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer](plx-20251231xex32d2.htm)\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\nX\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n97.1\n\n​\n\n[Policy Relating to Recovery of Erroneously Awarded Compensation](https://www.sec.gov/Archives/edgar/data/1006281/000155837024003161/plx-20231231xex97d1.htm)\n\n​\n\n10-K\n\n \n\n001-33357\n\n \n\n97.1\n\n​\n\nMarch 14, 2024\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n101.INS\n\n \n\nXBRL INSTANCE DOCUMENT - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\nX\n\n \n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n101.SCH\n\n \n\nXBRL SHEMA FILE\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\nX\n\n \n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n101.CAL\n\n \n\nXBRL CALCULATION FILE\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\nX\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n101.DEF\n\n \n\nXBRL DEFINITION FILE\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\nX\n\n \n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n101.LAB\n\n \n\nXBRL LABEL FILE\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\nX\n\n \n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n101.PRE\n\n \n\nXBRL PRESENTATION FILE\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\n​\n\n \n\nX\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n104\n\n​\n\nCover Page Interactive Data File - formatted in Inline XBRL and included as Exhibit 101\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nX\n\n†     Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.\n\n††   Portions of this exhibit were omitted and have been filed separately with the Secretary of the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 of the Exchange Act."}